REG - Destiny Pharma PLC - Exercise of Options and Total Voting Rights

Destiny PharmaAnnouncement

26/01/2023 10:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230126:nRSZ9719Na&default-theme=true

RNS Number : 9719N  Destiny Pharma PLC  26 January 2023

Destiny Pharma plc

("Destiny Pharma" or "the Company")

 

Exercise of Options and Total Voting Rights

 

Brighton, United Kingdom - 26 January 2023 - Destiny Pharma (AIM: DEST), a
clinical stage innovative biotechnology company focused on the development of
novel medicines that can prevent life threatening infections, announces that
it has issued and allotted 150,000 new ordinary shares of 1 pence each in the
capital of the Company (the "New Ordinary Shares") following an exercise of
share options by a former director.

Application will be made to the London Stock Exchange for the New Ordinary
Shares to be admitted to trading on AIM, with dealings expected to commence on
01 February 2023 ("Admission").

Following Admission, the Company will have a total of 73,457,105 Ordinary
Shares in issue. Shareholders may use this figure of 73,457,105 Ordinary
Shares as the denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change to their interest
in, the share capital of the Company under the FCA's Disclosure Guidance and
Transparency Rules.

 

For further information, please contact:

Destiny Pharma plc
Neil Clark, CEO

Shaun Claydon, CFO

+44 (0)1273 704 440
pressoffice@destinypharma.com
(https://otp.tools.investis.com/clients/uk/destiny_pharma_ltd/rns/about%3Ablank)

Optimum Strategic Communications
Mary Clark / Nick Bastin / Manel Mateus / Eleanor Cooper
+44 (0) 203 922 0891

DestinyPharma@optimumcomms.com
(https://otp.tools.investis.com/clients/uk/destiny_pharma_ltd/rns/about%3Ablank)

finnCap Ltd (Nominated Advisor and Joint Broker)
Geoff Nash / George Dollemore, Corporate Finance

Alice Lane / Nigel Birks / Harriet Ward, ECM

+44 (0) 207 220 0500

Shore Capital (Joint Broker)

Daniel Bush / James Thomas / Lucy Bowden

+44 (0) 207 408 4090

MC Services AG
Anne Hennecke / Andreas Burckhardt

+49-211-529252-12

Stern IR - US

Janhavi Mohite

+1-212-362-1200

Janhavi.Mohite@sternir.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRUNRRROBUAUAR